Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GLEAM
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
- NCT03816163 ↗
- Active, not recruiting
- Astellas Pharma Global Development, Inc.
- Deep
We haven't built an HCP commentary report on GLEAM (zolbetuximab, nab-paclitaxel and 1 more in Pancreatic Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GLEAM so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 17 | |
| YouTube | 4 | |
| Podcasts | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
- Interventions
- zolbetuximab; nab-paclitaxel; gemcitabine
- Arms
- zolbetuximab +nab-paclitaxel + gemcitabine · Experimental
- nab-paclitaxel + gemcitabine · Active comparator
- Enrollment
- 393
- Primary outcomes
- Dose Limiting Toxicities (DLT) - (safety lead in)
- Overall Survival (OS)
- Safety assessed by Adverse Events (AEs)
- Safety assessed by incidence of serious adverse events (SAE)
- Safety assessed by incidence of treatment emergent adverse events (TEAE)
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)
- Number of participants with vital sign abnormalities and /or adverse events (AEs)
- Number of participants with electrocardiograms (ECG) abnormalities and or adverse events
- Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events
- Sponsor
- Astellas Pharma Global Development, Inc.
- Start
- Mar 15, 2019
- Primary completion
- Oct 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03816163 · updated Oct 14, 2026